Novartis Investigative Site

York YO31 8HE

0 studies enrolling now · 10 studies all time

What they study most

Acute Heart Failure, Atherosclerosis, Breast Cancer, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Non-infectious Uveitis, Tuberous Sclerosis Complex, Tuberous Sclerosis Complex-associated Refractory Seizures, Uveitis

Studies at this site

• Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment — Running, not enrolling
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis — Stopped early
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis — Stopped early
• Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis — Stopped early